- Home
- BEAT vs DTIL Comparison
BEAT vs DTIL Comparison
Compare BEAT & DTIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BEAT
- DTIL
- Stock Information
- Founded
- BEAT 2015
- DTIL 2006
- Country
- BEAT United States
- DTIL United States
- Employees
- BEAT N/A
- DTIL N/A
- Industry
- BEAT Retail: Computer Software & Peripheral Equipment
- DTIL Biotechnology: Pharmaceutical Preparations
- Sector
- BEAT Technology
- DTIL Health Care
- Exchange
- BEAT Nasdaq
- DTIL Nasdaq
- Market Cap
- BEAT 51.1M
- DTIL 51.6M
- IPO Year
- BEAT 2021
- DTIL 2019
- Fundamental
- Price
- BEAT $1.35
- DTIL $4.21
- Analyst Decision
- BEAT Buy
- DTIL Strong Buy
- Analyst Count
- BEAT 1
- DTIL 2
- Target Price
- BEAT $8.00
- DTIL $47.00
- AVG Volume (30 Days)
- BEAT 175.9K
- DTIL 527.4K
- Earning Date
- BEAT 08-13-2025
- DTIL 07-31-2025
- Dividend Yield
- BEAT N/A
- DTIL N/A
- EPS Growth
- BEAT N/A
- DTIL N/A
- EPS
- BEAT N/A
- DTIL N/A
- Revenue
- BEAT N/A
- DTIL $51,141,000.00
- Revenue This Year
- BEAT N/A
- DTIL N/A
- Revenue Next Year
- BEAT N/A
- DTIL $30.20
- P/E Ratio
- BEAT N/A
- DTIL N/A
- Revenue Growth
- BEAT N/A
- DTIL N/A
- 52 Week Low
- BEAT $1.21
- DTIL $3.61
- 52 Week High
- BEAT $3.48
- DTIL $11.09
- Technical
- Relative Strength Index (RSI)
- BEAT 37.47
- DTIL 38.34
- Support Level
- BEAT $1.49
- DTIL $4.06
- Resistance Level
- BEAT $1.62
- DTIL $4.97
- Average True Range (ATR)
- BEAT 0.11
- DTIL 0.36
- MACD
- BEAT -0.02
- DTIL -0.09
- Stochastic Oscillator
- BEAT 7.44
- DTIL 18.06
About BEAT Heartbeam Inc.
HeartBeam Inc is a medical technology company primarily focusing on developing and commercializing higher resolution ambulatory Electrocardiogram ("ECG") solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The Company's ability to develop higher-resolution ECG solutions is achieved through the development of the Company's proprietary and patented Vector Electrocardiography ("VECG") technology platform. The Company has validated this technology and is seeking U.S. Food and Drug Administration ("FDA") clearance for its initial telehealth products.
About DTIL Precision BioSciences Inc.
Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.